The Lens platform is designed to provide scientists and researchers across biotechnology and pharmaceutical companies with short-term, on-demand access to more than 35 petabytes of de-identified clinical and molecular datasets. The platform includes AI analytical tools intended to accelerate drug discovery and development.

The platform enables users to access, analyze, and build upon Tempus' library of data in an optimized environment equipped with the tools needed to extract insights in minutes, the company stated in a release.

New algorithm helps integrate single-cell data from around the globe
A new algorithm enables researchers from around the globe to integrate multiple single-cell datasets from a variety of omics platforms in a quick and...

Relay Therapeutics acquires ZebiAI for $85M
Relay Therapeutics has acquired ZebiAI, a developer of experimental DNA-encoded library datasets using machine learning for drug discovery. Relay hopes...

AbCellera, Empirico use advanced computation to discover novel antibodies
AbCellera has entered into a strategic, multitarget collaboration with Empirico to discover novel therapeutic antibodies.

X-ray crystallography identifies drugs to be repurposed for COVID-19
A new large-scale study indicates x-ray crystallography can be used to find drugs that could be repurposed to target the SARS-CoV-2 main protease. In...

Machine-learning system ranks most effective cancer drugs
Scientists successfully trained an ensemble of machine-learning (ML) algorithms to rank clinically relevant cancer drugs based on the drugs' predicted...